Jun 08,2022

Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With MDI: An Analysis Based on the GOLD Randomized Trial (GOLD 8)

The study evaluated whether patients with type 1 diabetes managed with multiple daily insulin injections (MDI) exercised more after initiating continuous glucose monitoring (CGM) and whether the improved glycemic control and well-being associated with CGM translates into improved blood lipids and markers of inflammation.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2022

Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems

The study reviews attributes of Dexcom’s fifth-, sixth-, and seventh-generation (G5, G6, and G7) CGM systems.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2022

Explainable Machine Learning for Real-Time Hypoglycemia and Hyperglycemia Prediction and Personalized Control Recommendations

The study assesses the efficiency and effectiveness of machine learning algorithms using CGM data to make ahead-of-time risk predictions and provide insight into an individual’s longer term control, hypoglycemia and hyperglycemia peaks.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

Dexcom focuses on early diabetes diagnosis as COVID links emerge

New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker discussed the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

DEXCOM AND ROCHE COLLABORATE FOR THE DISTRIBUTION OF THE CONTINUOUS REAL-TIME GLUCOSE MONITORING SYSTEM DEXCOM ONE IN ITALY

DexCom, Inc. ( NASDAQ: DXCM ), a world leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that it has signed a definitive agreement with Roche Diabetes Care for the distribution in Italy of the Dexcom ONE real-time CGM system.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Analysis of “Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes”

This study analyzes the article by Laffell et al examining the accuracy and performance of a seventh-generation “G7” continuous glucose monitor (CGM) system in participants with type 1 diabetes aged 2 to 17 years.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Safety and Functional Integrity of CGM Sensors When Used During Radiologic Procedures Under High Exposure Conditions

The study investigates wearable components of the Abbott Diabetes Care FreeStyle Libre® (continuous glucose monitoring [CGM 1), FreeStyle Libre® 2 (CGM 2), and FreeStyle Libre® 3 (CGM 3) systems in simulated diagnostic radiologic procedures.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 01,2022

Smart Pen Exposes Missed Basal Insulin Injections and Reveals the Impact on Glycemic Control in Adults With Type 1 Diabetes

Adherence to basal insulin injections and the effects of missed basal insulin injections in adults with type 1 diabetes (T1D) were investigated using data from continuous glucose monitoring (CGM) and smart insulin pen devices in a real-world study.

CLINICAL STUDY

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 07,2022

Zillion Partners with Dexcom to Integrate Continuous Glucose Monitoring (CGM) Data with its RestoreHealth Program

Zillion announced today its partnership with Dexcom, the leader in real-time continuous glucose monitoring (CGM), to connect Dexcom CGM with Zillion’s platform for use with their RestoreHealth program. This partnership will continue to enhance the RestoreHealth offering to employer and health system patients.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM